Insulin–Glucokinase AAV Composition for Glycemic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diabetes, particularly type 1 and type 2 diabetes, struggle with maintaining tight glycemic control, leading to severe complications and are limited in accessibility, especially in underdeveloped countries, necessitating a more effective and accessible treatment approach.
Innovation Solution
A combination gene therapy using AAV vectors encoding insulin and glucokinase expression cassettes, administered at specific vector ratios, to enhance insulin production and glucose regulation in diabetic subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lifelong insulin treatment is used, then diabetes management is achieved, but glycemic control is difficult to maintain tight and complications occur
Solution Approach 1:
The gene therapy enables the patient's own cells to produce insulin autonomously. The AAV vector delivers the insulin gene to pancreatic cells, which then self-produce insulin without requiring external injection, transforming the system from dependent on external intervention to self-sufficient.
Solution Approach 2:
The therapy performs preliminary action by delivering the insulin gene before the natural insulin production capacity is completely depleted. The AAV vector transduces pancreatic cells in advance, establishing endogenous insulin production capability before severe β-cell destruction occurs, thereby preventing the need for lifelong exogenous insulin.
2Reliability
If exogenous insulin is administered, then insulin deficiency is treated, but access is limited in underdeveloped countries leading to severe complications
Solution Approach 1:
The gene therapy creates a functional copy of the insulin gene within the patient's own cells. Instead of relying on external insulin products that require complex supply chains, the therapy inserts a functional copy of the insulin gene that can be transcribed and translated autonomously, eliminating dependence on imported pharmaceuticals.
Solution Approach 2:
The therapy extracts the insulin production capability from the external supply chain and relocates it within the patient's pancreatic cells. By removing the dependency on external insulin administration systems, the therapy eliminates the accessibility barrier that plagues underdeveloped countries with limited medical infrastructure.
3Ease of operation
If gene therapy is used, then lifelong insulin injections are reduced, but the therapy complexity increases
Solution Approach 1:
The therapy replaces the mechanical system of repeated needle injections with a biological system. Instead of mechanically administering insulin through daily injections, the AAV vector delivers genetic material that triggers biological insulin production, substituting a complex mechanical self-care routine with a one-time genetic intervention that activates cellular function.
Solution Approach 2:
The therapy segments the insulin production function from the patient's natural β-cells by using AAV vectors to deliver the insulin gene to remaining pancreatic cells. This segmentation allows the therapy to work with partial pancreatic function, dividing the insulin production task between the delivered gene and the patient's existing cellular infrastructure, thereby reducing the need for complete β-cell regeneration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The therapy effectively reduces glycated hemoglobin levels, regulates blood glucose, and decreases circulating ketones and triglycerides, potentially reducing the need for lifelong insulin injections and improving glycemic control.
Implementation Method 1
AAV vectors encoding insulin and glucokinase expression cassettes
Implementation Method 2
AAV vectors encoding insulin and glucokinase expression cassettes, administered at specific vector ratios
Data Source
AI summary
The present disclosure relates to a combination therapy comprising a first AAV vector genome comprising an insulin expression cassette; and a second AAV vector genome comprising a glucokinase expression cassette; wherein the first AAV vector genome and the second AAV vector genome are in a ratio selected from the group consisting of 1:0.25-0.75, 1:1.75-2.25, and 1:3.75-4.25, and methods for using the same for treating diabetes.